赫赛汀联合多西他赛对局部浸润性乳腺癌的疗效分析  

Analysis of the efficacy of breast cancer Herceptin and docetaxel

作　　者：方岳雨 孙慧[1] 

机构地区：[1]南京市浦口区中心医院肿瘤科,211800

出　　处：《辽宁医学杂志》2016年第5期1-3,共3页Medical Journal of Liaoning

摘　　要：目的探讨赫赛汀联合多西他赛在局部浸润性乳腺癌治疗中的疗效。方法将在2012年1月~2014年12月期间进入我院肿瘤科治疗的120例局部浸润性乳腺癌患者纳入课题研究,随机分为常规治疗组和研究组,各60例患者,常规治疗组采用多柔比星+环磷酰胺治疗,研究组在对照组基础上加用赫赛汀联合多西他赛治疗,共治疗8个疗程。观察治疗后乳腺癌组织标本的HMGI^C基因表达和血清C反应蛋白水平,评价两组疗效。结果与常规治疗组相比,研究组降低了HMGI-C阳性率(P<0.05);加用赫赛汀联合多西他赛后,升高了研究组的平均LI值、HER2阳性率、p53阳性率、雌激素受体阴性率(P<0.05);同时,降低了研究组血清CRP水平(P<0.05)。结论赫赛汀联合多西他赛能够提高局部浸润性乳腺癌的治疗效果,使患者HMGI-C和CRP的表达水平降低,进而使患者预后得到改善。Objective To investigate the effects and safety of Herceptin and docetaxel in the treatment of metastatic breast cancer. Methods 120 patients with metastatic breast cancer from January 2012 to December 2014 in our hospital were randomly divided into research group and routine group,60 cases in each group,routine group with soft doxorubicin plus cyclophosphamide therapy,research group in the routine group based on the use of Herceptin and docetaxel in the treatment were treated with eight cycles. HMGI-C expression and serum C reactive protein levels were observed in the breast cancer tissues,and the effect of the two groups were evaluated,and the adverse reactions were observed. Results The positive rate of HMGI-C in research group was significantly lower than that in routine group,and the difference was statistically significant（ P〈0. 05）. The average LI,HER2 positive rate,p53 positive rate,estrogen receptor negative rate were significantly higher than those in HMGI-C negative group（ P〈0. 05）; the serum CRP level in the research group was significantly lower than that in the routine group,P〈0. 05. Conclusion Herceptin combined with docetaxel in the treatment of local infiltration of metastatic breast cancer can reduce expression of HMGI-C and C-reactive protein（ CRP） and improve the prognosis of the patients.

关 键 词：局部浸润性乳腺癌 HMGI-C 赫赛汀 多西他赛 

分 类 号：R737.9[医药卫生—肿瘤]